Edition:
United States

Abiomed Inc (ABMD.O)

ABMD.O on Nasdaq

117.14USD
24 Feb 2017
Change (% chg)

$0.25 (+0.21%)
Prev Close
$116.89
Open
$116.00
Day's High
$117.50
Day's Low
$114.28
Volume
207,216
Avg. Vol
540,622
52-wk High
$132.95
52-wk Low
$79.23

Select another date:

Thu, Jan 26 2017

BRIEF-Abiomed Q3 GAAP earnings per share $0.34

* Abiomed announces Q3 FY 2017 revenue of $114.7 million, up 34% over prior year

BRIEF-Abiomed Q3 earnings per share $0.34

* Says increasing lower end of its fiscal year 2017 revenue guidance with new range of $440 million to $445 million

BRIEF-Abiomed announces preliminary q3 preliminary revenue

* Abiomed announces preliminary q3 fy 2017 revenue of $114.7 million, up 34% over prior year

BRIEF-Abiomed Q2 revenue of $103 million, up 35 pct over prior year

* Abiomed announces q2 fy 2017 revenue of $103 million, up 35% over prior year

BRIEF-Abiomed receives FDA ide approval for initiation of door to unloading prospective feasibility study

* Abiomed receives fda ide approval for initiation of door to unloading (dtu) prospective feasibility study

BRIEF-Abiomed receives FDA IDE approval for initiation of DTU prospective feasibility study

* Receives FDA IDE approval for initiation of door to unloading (DTU) prospective feasibility study

BRIEF-Abiomed reports Q2 FY 2017 gaap earnings per share $0.20

* Announces Q2 FY 2017 revenue of $103 million, up 35% over prior year

BRIEF-Abiomed Impella 2.5 and Impella 5.0 heart pumps receive regulatory approval from Japan Ministry of Health, Labor & Welfare

* Abiomed Impella 2.5 and Impella 5.0 heart pumps receive regulatory approval from Japan Ministry of Health, Labor & Welfare

Select another date:

More From Around the Web